Biocryst Pharmaceuticals Return on Equity

Biocryst Pharmaceuticals (BCRX) currently reports a ROE of 84.68%. That is above the Healthcare sector average of 21.28%. Use the charts on this page to explore Biocryst Pharmaceuticals's ROE history and peer comparisons.

Biocryst Pharmaceuticals's ROE of 84.68% is higher than the Healthcare sector average of 21.28%. That is roughly 297.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biocryst Pharmaceuticals's current 84.68% should be judged against Healthcare norms (sector average: 21.28%) and against BCRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 84.68%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Biocryst Pharmaceuticals, and consider following BCRX for alerts when major investors trade the stock.

Biocryst Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 84.68% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCRX with unrelated industries.